Pila Pharma (STO:PILA) H1 2024 results
Key financial results
- Sales: 683,000 crowns (38% less than in the first half of 2023).
- Net loss: 4.09 million crowns (loss reduced by 42% from H1 2023).
All figures shown in the graph above refer to the last 12 months (TTM)
Pila Pharma shares rose 6.4% compared to the previous week.
Risk analysis
You should always think about the risks. A typical example: We have 5 warning signs for Pila Pharma You should be aware of these, and three of them make us uncomfortable.
New: Manage all your stock portfolios in one place
We have the the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of portfolios and see your total amount in one currency
• Be notified of new warning signals or risks by email or mobile phone
• Track the fair value of your stocks
Try a demo portfolio for free
Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.
This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.
